Enquirer Consulting Group

Reachable Buyer Map

Prepared for Edward Perper, MD · Science Branding Communications · September 2026
Here is the map Sophie promised. Your site describes SBC's audience as Pharmaceutical and Biotech Science Communicators, and your own description of the work is translating clinical evidence into stories that move physicians, payers and investigators, for medical affairs teams, commercial teams, life science agencies and academic experts. So this page maps the US companies that hold clinical evidence and have to persuade somebody with it: which groups they fall into, who inside each one commissions the work, and roughly how many exist. It maps the market around SBC, not SBC itself, and there is nothing to buy at the end of it.
Where the commissioning decision actually sits
Six rows. The first is the whole population of companies with an active clinical program in the US; rows two and three are cuts inside it and are not additional companies. Rows four and five are different registers of the same market and overlap row one heavily. Counts are banded on purpose and count companies, except where the row says otherwise.
Companies running a clinical study in the US right now
Commercial sponsors with at least one study recruiting, active or about to open at a US site. This is the closest public thing to a list of companies that currently hold clinical evidence and will have to explain it to somebody.
Who commissions it: the VP or Head of Medical Affairs owns the scientific narrative and usually holds the budget. Director or VP of Medical Communications runs the work itself. On the commercial side the Brand or Product Director buys the launch-facing version.
Who shapes it without holding the budget: the Publications Manager or Director of Scientific Publications, who owns manuscripts and congress abstracts and is usually the first person to feel the gap.
About 3,100
distinct commercial sponsors across 8,742 active US studies. Sponsor names are free text in the register, so a company filing under several spellings is counted more than once. Read this as a ceiling.
The one-study companies inside that group
Sponsors with exactly one active US study. One asset, one story, and at that size rarely anyone in house whose whole job is the narrative. They are three in five of every sponsor on the register and they hold about a fifth of the studies.
Who commissions it: most often the Chief Medical Officer, because a company this size has not built a separate medical affairs department yet. Where there is a commercial hire, it is frequently the first one.
About 1,930
sponsors with a single active US study. A subset of the row above, not an addition to it.
The heavy sponsors inside that group
Companies running twenty or more active US studies at once, the largest of them close to three hundred. Forty companies hold a third of the entire active pipeline. These have in-house medical communications functions and standing agency rosters already, so the way in is a roster decision rather than a first purchase.
Who commissions it: Global or US Head of Medical Affairs and the Head of Medical Communications, with procurement running the roster review on a fixed cycle.
40
sponsors with twenty or more active US studies. They hold 2,932 of the 8,742 studies. A subset of the first row.
Companies registered with the FDA as US drug establishments
The supply side of the US drug market as the federal register defines it. This is a wider net than the clinical rows and catches commercial-stage companies whose studies have finished, which are exactly the ones with a label to defend rather than a story to launch.
Who commissions it: Medical Affairs at commercial-stage companies, and Market Access or HEOR where the audience is a payer. Treat that as a separate commissioning lane: a payer value narrative is bought by different people, on a different cycle, from physician-facing work.
About 3,500
distinct company names across about 5,300 US-addressed registered establishments. One company registers several sites, which is why the company count is well below the site count. Registration is a compliance fact and says nothing about revenue or size.
Companies already paying US clinicians to speak and consult
Manufacturers that file annual reports of payments made to US physicians and teaching hospitals. The value of this row is not its size, it is what it proves: every company on it has already decided that persuading clinicians is worth a budget line, and files the number publicly every year.
Who commissions it: Medical Affairs holds the speaker and advisory programs these payments fund, so the same seat that funds the physician engagement funds the material behind it.
About 1,650
US reporting entities in the most recently published program year. Deduplicated at company level, with spend attached to each.
Life science agencies and academic experts
Your own description names both as people SBC works with, and neither is enumerable. No public register lists medical communications agencies, and academic experts are individuals rather than organizations. Rather than show a number built on a guess, this row carries none. It is built by name, from congress programs, publication author lists and agency rosters, not counted.
Who commissions it: at an agency, the Scientific Services or Medical Strategy lead, who buys capacity and specialist depth rather than a program. For an academic expert the work is usually funded by the sponsor behind the study, not by the expert.
No public count
not carried by any public register, so this segment is built by name rather than counted.
The same market, cut the way the buyer is organized
Medical affairs teams are built by therapeutic area, not by company size, so this is the cut that matches how the buyer actually sits. These are the areas listed on your own profile. The rows overlap, because one study can sit in more than one area, and they do not sum to the total above.
Therapeutic area Companies Active US studies Of those companies, how many run just one
Oncology1,0533,166651
Neurology and CNS6201,197431
Cardiology5481,072389
Pulmonology5131,139364
Autoimmune disease167442109
Diabetes162286118
Rheumatology12023280
Obesity7421754
Rare diseaseNo honest count. The register indexes studies by the specific disease, never by the rare-disease label, so any number here would be an artifact of the query rather than a reading of the market. It is real and it is large, and it has to be built disease by disease.

Where the openings are

1
The one-study companies are the largest group on this page and the least likely to already have someone. About 1,930 companies have exactly one active US study. At that size there is usually no medical communications department, no agency roster and no publications lead, and the Chief Medical Officer is carrying the narrative personally alongside everything else. They are also the hardest group to reach by referral, because each one is a first conversation rather than an extension of an existing relationship.
2
Forty companies hold a third of the pipeline, and they are a different motion entirely. Getting onto a standing roster is a procurement cycle with a fixed review date, not a conversation that starts when the need appears. Both groups are real markets and they need opposite approaches. The practical question is which of the two you want a repeatable engine for, because a single motion built for one will underperform badly against the other.
3
Every area in the table is small enough to work as a named list rather than a sample. The largest is about a thousand companies and most are in the hundreds. At that size you can reach every company in an area, in the language of that area, and know you have covered it, which is a different exercise from broad prospecting. Cardiology is the obvious place to start given where you come from, and at 548 companies it is a list rather than a market.
Built from public federal registries and the public clinical trial register, pulled 18 September 2026. Counts are banded deliberately. Company counts drawn from the trial register are a ceiling, because sponsor names are entered as free text and one company can appear under several spellings. A segment with no credible public number says so rather than showing one.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com